Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2018 Oct 24;293(48):18730–18735. doi: 10.1074/jbc.TM118.003339

The antizyme family for regulating polyamines

Chaim Kahana 1,1
PMCID: PMC6290168  PMID: 30355739

Abstract

The polyamines spermidine, spermine, and their precursor putrescine are organic polycations involved in various cellular processes and are absolutely essential for cellular proliferation. Because of their crucial function in the cell, their intracellular concentration must be maintained at optimal levels. To a large extent, this regulation is achieved through the activity of an autoregulatory loop that involves two proteins, antizyme (Az) and antizyme inhibitor (AzI), that regulate the first enzyme in polyamine biosynthesis, ornithine decarboxylase (ODC), and polyamine uptake activity in response to intracellular polyamine levels. In this Minireview, I will discuss what has been learned about the mechanism of Az expression and its physical interaction with both ODC and AzI in the regulation of polyamines.

Keywords: biophysics, cancer, cell biology, cell growth, enzyme inactivation, enzyme degradation, inhibitor, polyamine, antizyme, antizyme inhibitor, frameshifting, ornithine decarboxylase, polyamines, frameshifting, ubiquitin-dependent, ubiquitin-independent

Introduction

The polyamines spermidine, spermine, and their precursor putrescine perform essential cellular roles, and most notable is their role in supporting cellular proliferation (1). For maximal effectiveness, optimal levels of polyamines must be maintained under varying physiological conditions. This requirement is fulfilled by tight regulation of key enzymes of their biosynthesis and catabolic pathways (Fig. 1). The biosynthesis pathway begins with the conversion of ornithine to putrescine by the action of ornithine decarboxylase (2). Putrescine is then converted to spermidine and spermidine to spermine by the sequential action of the two aminopropyltransferases, spermidine synthase and spermine synthase (35). These two enzymes utilize decarboxylated SAM2 that is generated by the action of adenosylmethionine decarboxylase on SAM as an aminopropyl donor (6). Polyamines can be interconverted through the direct action of spermine oxidase or indirectly by polyamine oxidase that acts on spermine and spermidine after their acetylation by spermine/spermidine-N1-acetyltransferase (79). Although the biosynthesis and interconversion pathways can be regulated at several steps, the most notable regulation in this pathway is that of ODC (Fig. 1).

Figure 1.

Figure 1.

Biosynthesis and interconversion of polyamines. The abbreviations used are as follows: SAMDC, SAM decarboxylase; SSAT, spermidine/spermine N1-acetyltransferase; SMO, spermine oxydase; PAO, polyamine oxydase.

ODC is active as a loose homodimer that exists in a constant state of association and dissociation (Fig. 2) (1013). The rapid exchange of ODC subunits is a key trait enabling its regulation by a unique polyamine-induced protein called antizyme (Az) (1416). Az, a small polyamine-induced protein, is a central player in an autoregulatory loop that adjusts cellular polyamines (Fig. 2) and is found in animalia, fungi, and protista (17). Az binds ODC subunits with higher affinity than these subunits display to each other. The formation of the ODC–Az heterodimers results not only in the obvious inactivation of ODC but also in targeting ODC to ubiquitin-independent degradation by the 26S proteasome (Fig. 2) (18, 19). Polyamines regulate the synthesis of Az by stimulating a ribosomal frameshifting (20, 21) that serves as a sensor of cellular polyamines. As a central element of the autoregulatory loop regulating cellular polyamine, it is not surprising that Az also negatively regulates polyamine uptake activity (Fig. 2) (2224) via a yet unresolved mechanism. The term Az relates to a family of three members and a putative fourth member, termed Az1, Az2, Az3, and Az4 (17, 25). Interestingly, Az itself is regulated by another protein termed antizyme inhibitor (AzI) that is highly homologous to ODC but lacks ornithine-decarboxylating activity (Fig. 2) (26). A high concentration of polyamines represses AzI expression by promoting the expression of an upstream open reading frame (ORF) initiated at a noncognate codon (27, 28).

Figure 2.

Figure 2.

Regulation of ODC degradation. ODC is a loosely bound homodimer that easily dissociates into monomers. ODC is the first in a chain of enzymes involved in the synthesis of polyamines. Polyamines stimulate a +1 frameshifting event leading to the synthesis of active Az. Az, which has a higher affinity for ODC monomers compared with the affinity ODC monomers have to each other, traps them and delivers them to the 26S proteasome where they are recognized and degraded without requiring ubiquitination. Az is not degraded while delivering ODC to the proteasome. Instead, it is released to support another round of ODC degradation or is independently degraded by the proteasome in a ubiquitin-dependent process. Az also inhibit polyamine uptake via a yet unresolved mechanism. Az functions are negated by AzI, a monomeric nonfunctional homologue of ODC, whose synthesis is repressed by polyamines that stimulate translation of an upstream ORF. Like Az, AzI is also subjected to ubiquitin-dependent proteasomal degradation.

Az is expressed via a polyamine-stimulated ribosomal frameshift

Az proteins are encoded by partially overlapping ORFs. A unique process of ribosomal frameshifting is required to fuse these two ORFs to produce a completely functional Az protein (20, 21). The first short ORF is terminated by an in-frame termination codon, whereas the functional Az protein is encoded predominantly by the second long ORF. Therefore, the translating ribosomes must be subverted from the first to the second ORF via a rather inefficient frameshifting that is stimulated by polyamines. The frameshifting site is composed of an essential stop codon and a preceding triplet that in most cases is UCC. The ribosome encountering the UCC codon shifts to the +1 frame (Fig. 3) (21). Interestingly, although when tested all three stop codons are equally efficient (20, 21, 29), in the vast majority of cases UGA is the stop codon that ends ORF1. Frameshifting efficiency is enhanced by recoding signals that are part of the RNA located both 5′ and 3′ to the frameshifting site (Fig. 3) (30). The 5′-stimulatory segment that is composed of about 50 nucleotides can be divided into three modules whose conservation and importance increase toward the stop codon (Fig. 3) (17, 20, 21). 3′ to the stop codon, one finds a stimulatory pseudoknot and a nucleotide supporting the least efficient termination located just 3′ to the stop codon (Fig. 3) (17).

Figure 3.

Figure 3.

Synthesis of Az. Translation of Az mRNA initiates at one of two in-frame initiation codons. The longer form harbors a mitochondrial localization signal. The scanning ribosome encounters a stop codon at the end of ORF1, completing translation of the first ORF (ORF1). The sequence around this stop codon mediates the ribosomal shift to the +1 frame to translate ORF2 that encodes the mature functional Az. The increase in the free intracellular concentration of polyamines stimulates this frameshifting event. Sequences located 5′ and 3′ to the frameshifting site stimulate frameshifting efficiency.

Interestingly, in the budding yeast Saccharomyces cerevisiae, the recoding signals actually reduce the otherwise high-efficiency frameshifting (31). It was demonstrated that the nascent Az polypeptide acts in cis as a polyamine sensor that negatively regulates frameshifting. When the polyamine concentration is low, the growing polypeptide inhibits downstream translation, whereas the increased concentration permits completion of Az's translation (31). A combined regulation of frameshifting by the growing polypeptide and by the nucleotide sequence of a 3′-stimulator was also demonstrated (32).

A family of Az proteins

Mammalian cells contain a family of Az proteins. There are three well-characterized paralogs: Az1, Az2, and Az3 and a less characterized putative member termed Az4 (25). Two of these members, Az1 and Az2, are ubiquitously expressed; however, Az2 is expressed to much lower levels (33). Nevertheless, Az2 displays higher evolutionary conservation compared with Az1, perhaps suggesting added functional value. Although Az1 targets ODC to degradation both in vivo and in vitro, Az2 inactivates ODC in both systems but fails to support its degradation in vitro (34, 35). This difference was attributed to Arg131 and Ala145, whose simultaneous conversion to Asp severely inhibited in vitro activity of Az1 (36). The third member, Az3 appears to be tissue-specific being expressed predominantly in testis during certain stages of spermatogenesis (37, 38). Although the frameshifting sequence UCCUGA is present in all three Az proteins, the 3′-recoding pseudoknot is not found in Az3 (37). All three Az proteins inhibit ODC activity and polyamine uptake; however, Az3 fail to stimulate ODC degradation (35). However, this should be tested in cells that naturally express Az3, as it was suggested that the physiological role of Az3 is to prevent overaccumulation of ODC after the stage of spermatogenesis at which it is required (37).

Translation of Az1 is initiated at two in-frame initiation codons resulting in the synthesis of two isoforms (Fig. 3) (39). The second AUG is utilized more efficiently because it is located within an optimal consensus sequence for translation initiation. The longer form is localized in the mitochondria as the segment located between the two initiation codons contains a mitochondrial localization signal (Fig. 3) (39). The mitochondrial localization signal is missing in Az2 and in Az3 (37).

Antizyme inhibitors

Remarkably, Az is itself regulated by a protein termed AzI. AzI is highly homologous to ODC, but it retains no ornithine-decarboxylating activity (26, 40). Several independent reasons were suggested to account for the lack of ornithine-decarboxylating activity. AzI fails to form homodimers under physiological conditions (41), most likely due to differences in four amino acids from the dimer interface (42). This prevents the formation of an active site that in the case of ODC is located at the interface between the interacting subunits (13). In addition, AzI does not bind pyridoxal phosphate, an essential co-factor of ornithine decarboxylase (41). The affinity of AzI to Az is significantly higher than that of ODC, and therefore it rescues ODC from interaction with Az and degradation (26, 44, 45). In addition to the monomeric nature of AzI that makes it more available for interaction with Az, it was suggested that residues 125 and 140 from the Az-binding site are responsible for its higher affinity to Az (46). The ability of AzI to save ODC from degradation is emphasized by the observed elevation of ODC and of polyamine uptake activity in AzI-overexpressing cells (47). Moreover, these changes result in increased growth rate, growth in low serum, anchorage-independent growth in soft agar, and tumor development when injected into nude mice.

A second ODC-related protein, initially called ODC-like or ODCp (48, 49), was eventually characterized as AzI and named AzI2 (4852). The originally identified AzI, AzI1, is ubiquitously expressed in rapidly proliferating cells, and AzI2 is expressed predominantly in differentiated testicular and neural cells and in secretory cells of various tissues (48, 5357). A third member of the ODC family that was recently suspected as an additional AzI was eventually demonstrated as a leucine decarboxylase (58).

Degradation of Az and AzI

Az arrives to the 26S proteasome together with ODC. However, although ODC is degraded, Az is spared and is recycled to support additional rounds of degradation (Fig. 2) (59), or it is subjected to ubiquitin-dependent degradation (60). In yeast, polyamines not only stimulate Az synthesis by promoting frameshifting, but they also inhibits its ubiquitin-dependent degradation (61).

As AzI is highly homologous to ODC, it is not surprising that it is also a rapidly degrading protein. However, like Az, its degradation is ubiquitin-dependent and is not stimulated by Az (62). Actually, interaction with Az stabilizes AzI, apparently by inhibiting its ubiquitination (Fig. 2) (62). The long-term destiny of the AzI–Az complex is not presently known.

Interaction of Az with ODC and AzI

Two elements of a protein are required for its proteasomal degradation. The first is a segment mediating its recognition by the proteasome. Usually such segment mediates polyubiquitination of the target protein mediating its recognition by the proteasome. The second is an unstructured region that enables the initial penetration of the protein into the proteolytic cavity of the proteasome (63, 64). Two segments of ODC were demonstrated to be required for its ubiquitin-independent degradation (6568). One region containing amino acids 117–140 serves as the Az-binding site. The second is the most C-terminal segment encompassing amino acids 424–461 that appear to act as a degron, as it can be appended to stable proteins imposing on them rapid degradation (65, 66, 6971). In most rapidly degraded proteins, the recognition and infiltration regions are physically separated. In the case of ODC, it was originally thought that both are harbored within the unstructured C-terminal segment (72, 73). Interestingly, in its native context the C-terminal segment functions rather inefficiently unless ODC interact with Az. It was suggested that the C-terminal region is buried within the structure of the native dimeric ODC and becomes exposed upon interaction with Az (74, 75). However, more recent structural studies suggested that interaction with Az does not alter the structure of the most C-terminal segment of ODC, but rather it changes the structure of an adjacent segment encompassing amino acids 395–421 that might be involved in mediating the recognition of the ODC–Az complex by the proteasome (76, 77). Compatible with this possibility is the demonstration that the ODC mutant lacking amino acids 424–461 interacts efficiently with the proteasome but remains stable (77). It was therefore suggested that amino acids 395–421 mediate recognition by the proteasome, whereas amino acids 424–461 initiate the entrance into the proteasome.

Like ODC, Az also contains two segments required for stimulating ODC degradation: a large C-terminal segment that mediates binding to ODC, and an N-terminal segment that stimulates the degradation (19, 34, 78). The close proximity of the proteasome recognition segment of ODC to Az (77) may suggest that segment of Az together with a segment of ODC constitute a complete recognition signal.

The C-terminal segment of AzI does not display significant homology to the C-terminal segment of ODC. Nevertheless, AzI is rapidly degraded in a ubiquitin-dependent manner. Because interaction with Az interferes with its ubiquitination (62), it was suggested that this interaction imposes conformational changes that interfere with the ubiquitination process. Because the potentially ubiquitinated lysine residues of AzI are not masked by interacting with Az, it was suggested that this interaction may interfere with the recognition of AzI by the relevant E3 enzyme (77).

Az and AzI and cellular proliferation

ODC was suggested to act as an oncogene as its forced expression leads to cellular transformation (79). Az was suggested to function as a tumor suppressor (80). Because the synthesis of Az is completely dependent on the cellular concentration of polyamine, its involvement in regulating components of the polyamine biosynthesis pathway is rather obvious. However, several studies raised the possibility that Az may target the degradation of some proliferation-related proteins that are alien to the polyamine metabolic pathway. This includes cyclin D1, Smad1, Aurora-A, and a p73 anti-apoptotic variant (8184). However, the observation that massive overexpression of Az does not inhibit proliferation of cells expressing trypanosomal ODC, a form of ODC that is refractory to Az action, suggests that these proteins are not efficient targets of Az (85). Furthermore, some of these proteins remained stable in an in vitro degradation assay, whereas Az stimulated the degradation of co-incubated ODC. Recently, it was reported that under specific conditions Az2 stimulates nuclear ubiquitin-independent degradation of c-Myc (86).

Various studies suggested that AzI expression is elevated in several types of tumors (8790), suggesting that AzI may act as an oncogene (80). Compatible with this suggestion are the observations that overexpression of AzI in NIH3T3 cells resulted in their transformation (47), and suppression of AzI levels decreased cell proliferation (91, 92). AzI can be even more effective than ODC in stimulating cellular proliferation and transformation as its overexpression stimulates both ODC and polyamine uptake activity. Furthermore, recent studies have demonstrated that increased A-to-I RNA editing of AzI leads to a gain-of-function phenotype leading to more aggressive tumor behavior (43, 9396). In one of these cases, the reported editing resulted in amino acid substitution yielding a protein with enhanced ability of neutralizing Az functions (93).

Conclusions

The recent characterization of the physical interactions of Az with ODC and AzI emphasized the need to further investigate the interaction of Az with ODC and AzI and the mechanism of recognition of ODC by the proteasome, including the identification of the proteasomal subunits involved in the recognition of ODC. Attention should be also given to resolving the mechanism by which Az and AzI are recognized by the ubiquitin system and to the mechanism by which Az regulates polyamine uptake. Of great interest will be the determination of the structural reason that despite their similarity drives AzI and ODC to ubiquitin-dependent and -independent degradation, respectively.

This work was supported by grant from the Israel Academy of Science and Humanities. This article is part of a series on “Polyamines,” written in honor of Dr. Herbert Tabor's 100th birthday. The author declares that he has no conflicts of interest with the contents of this article.

2
The abbreviations used are:
SAM
S-adenosylmethionine
ODC
ornithine decarboxylase
Az
antizyme
AzI
antizyme inhibitor
ORF
open reading frame.

References

  • 1. Pegg A. E. (2016) Functions of polyamines in mammals. J. Biol. Chem. 291, 14904–14912 10.1074/jbc.R116.731661 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Pegg A. E. (2006) Regulation of ornithine decarboxylase. J. Biol. Chem. 281, 14529–14532 10.1074/jbc.R500031200 [DOI] [PubMed] [Google Scholar]
  • 3. Ikeguchi Y., Bewley M. C., and Pegg A. E. (2006) Aminopropyltransferases: function, structure and genetics. J. Biochem. 139, 1–9 10.1093/jb/mvj019 [DOI] [PubMed] [Google Scholar]
  • 4. Pegg A. E. (2014) The function of spermine. IUBMB Life 66, 8–18 10.1002/iub.1237 [DOI] [PubMed] [Google Scholar]
  • 5. Pegg A. E., and Michael A. J. (2010) Spermine synthase. Cell. Mol. Life Sci. 67, 113–121 10.1007/s00018-009-0165-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Pegg A. E. (2009) S-Adenosylmethionine decarboxylase. Essays Biochem. 46, 25–45 10.1042/bse0460003 [DOI] [PubMed] [Google Scholar]
  • 7. Casero R. A., and Pegg A. E. (2009) Polyamine catabolism and disease. Biochem. J. 421, 323–338 10.1042/BJ20090598 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Battaglia V., DeStefano Shields C., Murray-Stewart T., and Casero R. A. (2014) Polyamine catabolism in carcinogenesis: potential targets for chemotherapy and chemoprevention. Amino Acids 46, 511–519 10.1007/s00726-013-1529-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Pegg A. E. (2008) Spermidine/spermine-N(1)-acetyltransferase: a key metabolic regulator. Am. J. Physiol. Endocrinol. Metab. 294, E995–E1010 10.1152/ajpendo.90217.2008 [DOI] [PubMed] [Google Scholar]
  • 10. Solano F., Peñafiel R., Solano M. E., and Lozano J. A. (1985) Equilibrium between active and inactive forms of rat liver ornithine decarboxylase mediated by l-ornithine and salts. FEBS Lett. 190, 324–328 10.1016/0014-5793(85)81311-9 [DOI] [PubMed] [Google Scholar]
  • 11. Poulin R., Lu L., Ackermann B., Bey P., and Pegg A. E. (1992) Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by α-difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites. J. Biol. Chem. 267, 150–158 [PubMed] [Google Scholar]
  • 12. Rosenberg-Hasson Y., Bercovich Z., and Kahana C. (1991) cis-Recognition and degradation of ornithine decarboxylase subunits in reticulocyte lysate. Biochem. J. 277, 683–685 10.1042/bj2770683 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Tobias K. E., and Kahana C. (1993) Intersubunit location of the active site of mammalian ornithine decarboxylase as determined by hybridization of site-directed mutants. Biochemistry 32, 5842–5847 10.1021/bi00073a017 [DOI] [PubMed] [Google Scholar]
  • 14. Hayashi S., Murakami Y., and Matsufuji S. (1996) Ornithine decarboxylase antizyme: a novel type of regulatory protein. Trends Biochem. Sci. 21, 27–30 10.1016/S0968-0004(06)80024-1 [DOI] [PubMed] [Google Scholar]
  • 15. Kahana C. (2009) Antizyme and antizyme inhibitor, a regulatory tango. Cell. Mol. Life Sci. 66, 2479–2488 10.1007/s00018-009-0033-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Coffino P. (2001) Antizyme, a mediator of ubiquitin-independent proteasomal degradation. Biochimie 83, 319–323 [DOI] [PubMed] [Google Scholar]
  • 17. Ivanov I. P., and Atkins J. F. (2007) Ribosomal frameshifting in decoding antizyme mRNA from yeast protists to humans: close to 300 cases reveal remarkable diversity despite underlying conservation. Nucleic Acids Res. 35, 1842–1858 10.1093/nar/gkm035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Murakami Y., Matsufuji S., Kameji T., Hayashi S., Igarashi K., Tamura T., Tanaka K., and Ichihara A. (1992) Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 360, 597–599 10.1038/360597a0 [DOI] [PubMed] [Google Scholar]
  • 19. Mamroud-Kidron E., Omer-Itsicovich M., Bercovich Z., Tobias K. E., Rom E., and Kahana C. (1994) A unified pathway for the degradation of ornithine decarboxylase in reticulocyte lysate requires interaction with the polyamine-induced protein, ornithine decarboxylase antizyme. Eur. J. Biochem. 226, 547–554 10.1111/j.1432-1033.1994.tb20079.x [DOI] [PubMed] [Google Scholar]
  • 20. Rom E., and Kahana C. (1994) Polyamines regulate the expression of ornithine decarboxylase antizyme in vitro by inducing ribosomal frame-shifting. Proc. Natl. Acad. Sci. U.S.A. 91, 3959–3963 10.1073/pnas.91.9.3959 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Matsufuji S., Matsufuji T., Miyazaki Y., Murakami Y., Atkins J. F., Gesteland R. F., and Hayashi S. (1995) Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell 80, 51–60 10.1016/0092-8674(95)90450-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Hoshino K., Momiyama E., Yoshida K., Nishimura K., Sakai S., Toida T., Kashiwagi K., and Igarashi K. (2005) Polyamine transport by mammalian cells and mitochondria: role of antizyme and glycosaminoglycans. J. Biol. Chem. 280, 42801–42808 10.1074/jbc.M505445200 [DOI] [PubMed] [Google Scholar]
  • 23. Mitchell J. L., Judd G. G., Bareyal-Leyser A., and Ling S. Y. (1994) Feedback repression of polyamine transport is mediated by antizyme in mammalian tissue-culture cells. Biochem. J. 299, 19–22 10.1042/bj2990019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Suzuki T., He Y., Kashiwagi K., Murakami Y., Hayashi S., and Igarashi K. (1994) Antizyme protects against abnormal accumulation and toxicity of polyamines in ornithine decarboxylase-overproducing cells. Proc. Natl. Acad. Sci. U.S.A. 91, 8930–8934 10.1073/pnas.91.19.8930 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Ivanov I. P., Gesteland R. F., and Atkins J. F. (2000) Antizyme expression: a subversion of triplet decoding, which is remarkably conserved by evolution, is a sensor for an autoregulatory circuit. Nucleic Acids Res. 28, 3185–3196 10.1093/nar/28.17.3185 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Fujita K., Murakami Y., and Hayashi S. (1982) A macromolecular inhibitor of the antizyme to ornithine decarboxylase. Biochem. J. 204, 647–652 10.1042/bj2040647 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Ivanov I. P., Loughran G., and Atkins J. F. (2008) uORFs with unusual translational start codons autoregulate expression of eukaryotic ornithine decarboxylase homologs. Proc. Natl. Acad. Sci. U.S.A. 105, 10079–10084 10.1073/pnas.0801590105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Ivanov I. P., Shin B.-S., Loughran G., Tzani I., Young-Baird S. K., Cao C., Atkins J. F., and Dever T. E. (2018) Polyamine control of translation elongation regulates start site selection on antizyme inhibitor mRNA via Ribosome queuing. Mol. Cell 70, 254–264.e6 10.1016/j.molcel.2018.03.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Petros L. M., Howard M. T., Gesteland R. F., and Atkins J. F. (2005) Polyamine sensing during antizyme mRNA programmed frameshifting. Biochem. Biophys. Res. Commun. 338, 1478–1489 10.1016/j.bbrc.2005.10.115 [DOI] [PubMed] [Google Scholar]
  • 30. Ivanov I. P., Matsufuji S., Murakami Y., Gesteland R. F., and Atkins J. F. (2000) Conservation of polyamine regulation by translational frameshifting from yeast to mammals. EMBO J. 19, 1907–1917 10.1093/emboj/19.8.1907 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Kurian L., Palanimurugan R., Gödderz D., and Dohmen R. J. (2011) Polyamine sensing by nascent ornithine decarboxylase antizyme stimulates decoding of its mRNA. Nature 477, 490–494 10.1038/nature10393 [DOI] [PubMed] [Google Scholar]
  • 32. Yordanova M. M., Wu C., Andreev D. E., Sachs M. S., and Atkins J. F. (2015) A nascent peptide signal responsive to endogenous levels of polyamines acts to stimulate regulatory frameshifting on antizyme mRNA. J. Biol. Chem. 290, 17863–17878 10.1074/jbc.M115.647065 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Ivanov I. P., Gestelend R. F., and Atkins J. F. (1998) A second mammalian antizyme: conservation of programmed ribosomal frameshifting. Genomics 52, 119–129 10.1006/geno.1998.5434 [DOI] [PubMed] [Google Scholar]
  • 34. Zhu C., Lang D. W., and Coffino P. (1999) Antizyme2 is a negative regulator of ornithine decarboxylase and polyamine transport. J. Biol. Chem. 274, 26425–26430 10.1074/jbc.274.37.26425 [DOI] [PubMed] [Google Scholar]
  • 35. Snapir Z., Keren-Paz A., Bercovich Z., and Kahana C. (2009) Antizyme 3 inhibits polyamine uptake and ornithine decarboxylase (ODC) activity, but does not stimulate ODC degradation. Biochem. J. 419, 99–103 10.1042/BJ20081874 [DOI] [PubMed] [Google Scholar]
  • 36. Chen H., MacDonald A., and Coffino P. (2002) Structural elements of antizymes 1 and 2 are required for proteasomal degradation of ornithine decarboxylase. J. Biol. Chem. 277, 45957–45961 10.1074/jbc.M206799200 [DOI] [PubMed] [Google Scholar]
  • 37. Ivanov I. P., Rohrwasser A., Terreros D. A., Gesteland R. F., and Atkins J. F. (2000) Discovery of a spermatogenesis stage-specific ornithine decarboxylase antizyme: antizyme 3. Proc. Natl. Acad. Sci. U.S.A. 97, 4808–4813 10.1073/pnas.070055897 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Tosaka Y., Tanaka H., Yano Y., Masai K., Nozaki M., Yomogida K., Otani S., Nojima H., and Nishimune Y. (2000) Identification and characterization of testis specific ornithine decarboxylase antizyme (OAZ-t) gene: expression in haploid germ cells and polyamine-induced frameshifting. Genes Cells 5, 265–276 10.1046/j.1365-2443.2000.00324.x [DOI] [PubMed] [Google Scholar]
  • 39. Gandre S., Bercovich Z., and Kahana C. (2003) Mitochondrial localization of antizyme is determined by context-dependent alternative utilization of two AUG initiation codons. Mitochondrion 2, 245–256 10.1016/S1567-7249(02)00105-8 [DOI] [PubMed] [Google Scholar]
  • 40. Murakami Y., Ichiba T., Matsufuji S., and Hayashi S. (1996) Cloning of antizyme inhibitor, a highly homologous protein to ornithine decarboxylase. J. Biol. Chem. 271, 3340–3342 10.1074/jbc.271.7.3340 [DOI] [PubMed] [Google Scholar]
  • 41. Albeck S., Dym O., Unger T., Snapir Z., Bercovich Z., and Kahana C. (2008) Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function. Protein Sci. 17, 793–802 10.1110/ps.073427208 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Su K.-L., Liao Y.-F., Hung H.-C., and Liu G.-Y. (2009) Critical factors determining dimerization of human antizyme inhibitor. J. Biol. Chem. 284, 26768–26777 10.1074/jbc.M109.007807 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Crews L. A., Jiang Q., Zipeto M. A., Lazzari E., Court A. C., Ali S., Barrett C. L., Frazer K. A., and Jamieson C. H. (2015) An RNA editing fingerprint of cancer stem cell reprogramming. J. Transl. Med. 13, 52 10.1186/s12967-014-0370-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Kitani T., and Fujisawa H. (1989) Purification and characterization of antizyme inhibitor of ornithine decarboxylase from rat liver. Biochim. Biophys. Acta 991, 44–49 10.1016/0304-4165(89)90026-3 [DOI] [PubMed] [Google Scholar]
  • 45. Murakami Y., Matsufuji S., Nishiyama M., and Hayashi S. (1989) Properties and fluctuations in vivo of rat liver antizyme inhibitor. Biochem. J. 259, 839–845 10.1042/bj2590839 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Liu Y.-C., Liu Y.-L., Su J.-Y., Liu G.-Y., and Hung H.-C. (2011) Critical factors governing the difference in antizyme-binding affinities between human ornithine decarboxylase and antizyme inhibitor. PLoS ONE 6, e19253 10.1371/journal.pone.0019253 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Keren-Paz A., Bercovich Z., Porat Z., Erez O., Brener O., and Kahana C. (2006) Overexpression of antizyme-inhibitor in NIH3T3 fibroblasts provides growth advantage through neutralization of antizyme functions. Oncogene 25, 5163–5172 10.1038/sj.onc.1209521 [DOI] [PubMed] [Google Scholar]
  • 48. Pitkänen L. T., Heiskala M., and Andersson L. C. (2001) Expression of a novel human ornithine decarboxylase-like protein in the central nervous system and testes. Biochem. Biophys. Res. Commun. 287, 1051–1057 10.1006/bbrc.2001.5703 [DOI] [PubMed] [Google Scholar]
  • 49. López-Contreras A. J., López-Garcia C., Jiménez-Cervantes C., Cremades A., and Peñafiel R. (2006) Mouse ornithine decarboxylase-like gene encodes an antizyme inhibitor devoid of ornithine and arginine decarboxylating activity. J. Biol. Chem. 281, 30896–30906 10.1074/jbc.M602840200 [DOI] [PubMed] [Google Scholar]
  • 50. López-Contreras A. J., Ramos-Molina B., Cremades A., and Peñafiel R. (2008) Antizyme inhibitor 2 (AZIN2/ODCp) stimulates polyamine uptake in mammalian cells. J. Biol. Chem. 283, 20761–20769 10.1074/jbc.M801024200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Kanerva K., Mäkitie L. T., Pelander A., Heiskala M., and Andersson L. C. (2008) Human ornithine decarboxylase paralogue (ODCp) is an antizyme inhibitor but not an arginine decarboxylase. Biochem. J. 409, 187–192 10.1042/BJ20071004 [DOI] [PubMed] [Google Scholar]
  • 52. Snapir Z., Keren-Paz A., Bercovich Z., and Kahana C. (2008) ODCp, a brain- and testis-specific ornithine decarboxylase paralogue, functions as an antizyme inhibitor, although less efficiently than AzI1. Biochem. J. 410, 613–619 10.1042/BJ20071423 [DOI] [PubMed] [Google Scholar]
  • 53. López-Garcia C., Ramos-Molina B., Lambertos A., López-Contreras A. J., Cremades A., and Peñafiel R. (2013) Antizyme inhibitor 2 hypomorphic mice. New patterns of expression in pancreas and adrenal glands suggest a role in secretory processes. PLoS ONE 8, e69188 10.1371/journal.pone.0069188 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Rasila T., Lehtonen A., Kanerva K., Mäkitie L. T., Haglund C., and Andersson L. C. (2016) Expression of ODC antizyme inhibitor 2 (AZIN2) in human secretory cells and tissues. PLoS ONE 11, e0151175 10.1371/journal.pone.0151175 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Kanerva K., Lappalainen J., Mäkitie L. T., Virolainen S., Kovanen P. T., and Andersson L. C. (2009) Expression of antizyme inhibitor 2 in mast cells and role of polyamines as selective regulators of serotonin secretion. PLoS ONE 4, e6858 10.1371/journal.pone.0006858 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Mäkitie L. T., Kanerva K., Sankila A., and Andersson L. C. (2009) High expression of antizyme inhibitor 2, an activator of ornithine decarboxylase in steroidogenic cells of human gonads. Histochem. Cell Biol. 132, 633–638 10.1007/s00418-009-0636-7 [DOI] [PubMed] [Google Scholar]
  • 57. Kanerva K., Mäkitie L. T., Bäck N., and Andersson L. C. (2010) Ornithine decarboxylase antizyme inhibitor 2 regulates intracellular vesicle trafficking. Exp. Cell Res. 316, 1896–1906 10.1016/j.yexcr.2010.02.021 [DOI] [PubMed] [Google Scholar]
  • 58. Lambertos A., Ramos-Molina B., Cerezo D., López-Contreras A. J., and Peñafiel R. (2018) The mouse Gm853 gene encodes a novel enzyme: leucine decarboxylase. Biochim. Biophys. Acta 1862, 365–376 10.1016/j.bbagen.2017.11.007 [DOI] [PubMed] [Google Scholar]
  • 59. Mangold U. (2005) The antizyme family: polyamines and beyond. IUBMB Life 57, 671–676 10.1080/15216540500307031 [DOI] [PubMed] [Google Scholar]
  • 60. Gandre S., Bercovich Z., and Kahana C. (2002) Ornithine decarboxylase-antizyme is rapidly degraded through a mechanism that requires functional ubiquitin-dependent proteolytic activity. Eur. J. Biochem. 269, 1316–1322 10.1046/j.1432-1033.2002.02774.x [DOI] [PubMed] [Google Scholar]
  • 61. Palanimurugan R., Scheel H., Hofmann K., and Dohmen R. J. (2004) Polyamines regulate their synthesis by inducing expression and blocking degradation of ODC antizyme. EMBO J. 23, 4857–4867 10.1038/sj.emboj.7600473 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Bercovich Z., and Kahana C. (2004) Degradation of antizyme inhibitor, an ornithine decarboxylase homologous protein, is ubiquitin-dependent and is inhibited by antizyme. J. Biol. Chem. 279, 54097–54102 10.1074/jbc.M410234200 [DOI] [PubMed] [Google Scholar]
  • 63. Prakash S., Tian L., Ratliff K. S., Lehotzky R. E., and Matouschek A. (2004) An unstructured initiation site is required for efficient proteasome-mediated degradation. Nat. Struct. Mol. Biol. 11, 830–837 10.1038/nsmb814 [DOI] [PubMed] [Google Scholar]
  • 64. Prakash S., Inobe T., Hatch A. J., and Matouschek A. (2009) Substrate selection by the proteasome during degradation of protein complexes. Nat. Chem. Biol. 5, 29–36 10.1038/nchembio.130 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Ghoda L., Phillips M. A., Bass K. E., Wang C. C., and Coffino P. (1990) Trypanosome ornithine decarboxylase is stable because it lacks sequences found in the carboxyl terminus of the mouse enzyme which target the latter for intracellular degradation. J. Biol. Chem. 265, 11823–11826 [PubMed] [Google Scholar]
  • 66. Ghoda L., van Daalen Wetters T., Macrae M., Ascherman D., and Coffino P. (1989) Prevention of rapid intracellular degradation of ODC by a carboxyl-terminal truncation. Science 243, 1493–1495 10.1126/science.2928784 [DOI] [PubMed] [Google Scholar]
  • 67. Li X., and Coffino P. (1992) Regulated degradation of ornithine decarboxylase requires interaction with the polyamine-inducible protein antizyme. Mol. Cell. Biol. 12, 3556–3562 10.1128/MCB.12.8.3556 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Rosenberg-Hasson Y., Bercovich Z., and Kahana C. (1991) Characterization of sequences involved in mediating degradation of ornithine decarboxylase in cells and in reticulocyte lysate. Eur. J. Biochem. 196, 647–651 10.1111/j.1432-1033.1991.tb15861.x [DOI] [PubMed] [Google Scholar]
  • 69. Li X., Zhao X., Fang Y., Jiang X., Duong T., Fan C., Huang C. C., and Kain S. R. (1998) Generation of destabilized green fluorescent protein as a transcription reporter. J. Biol. Chem. 273, 34970–34975 10.1074/jbc.273.52.34970 [DOI] [PubMed] [Google Scholar]
  • 70. Hoyt M. A., Zhang M., and Coffino P. (2003) Ubiquitin-independent mechanisms of mouse ornithine decarboxylase degradation are conserved between mammalian and fungal cells. J. Biol. Chem. 278, 12135–12143 10.1074/jbc.M211802200 [DOI] [PubMed] [Google Scholar]
  • 71. Loetscher P., Pratt G., and Rechsteiner M. (1991) The C terminus of mouse ornithine decarboxylase confers rapid degradation on dihydrofolate reductase. Support for the pest hypothesis. J. Biol. Chem. 266, 11213–11220 [PubMed] [Google Scholar]
  • 72. Almrud J. J., Oliveira M. A., Kern A. D., Grishin N. V., Phillips M. A., and Hackert M. L. (2000) Crystal structure of human ornithine decarboxylase at 2.1 A resolution: structural insights to antizyme binding. J. Mol. Biol. 295, 7–16 10.1006/jmbi.1999.3331 [DOI] [PubMed] [Google Scholar]
  • 73. Takeuchi J., Chen H., and Coffino P. (2007) Proteasome substrate degradation requires association plus extended peptide. EMBO J. 26, 123–131 10.1038/sj.emboj.7601476 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Li X., and Coffino P. (1993) Degradation of ornithine decarboxylase: exposure of the C-terminal target by a polyamine-inducible inhibitory protein. Mol. Cell. Biol. 13, 2377–2383 10.1128/MCB.13.4.2377 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Zhang M., Pickart C. M., and Coffino P. (2003) Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitin-independent substrate. EMBO J. 22, 1488–1496 10.1093/emboj/cdg158 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Wu D., Kaan H. Y., Zheng X., Tang X., He Y., Vanessa Tan Q., Zhang N., and Song H. (2015) Structural basis of ornithine decarboxylase inactivation and accelerated degradation by polyamine sensor antizyme1. Sci. Rep. 5, 14738 10.1038/srep14738 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Wu H.-Y., Chen S.-F., Hsieh J.-Y., Chou F., Wang Y.-H., Lin W.-T., Lee P.-Y., Yu Y.-J., Lin L.-Y., Lin T.-S., Lin C.-L., Liu G.-Y., Tzeng S.-R., Hung H.-C., and Chan N.-L. (2015) Structural basis of antizyme-mediated regulation of polyamine homeostasis. Proc. Natl. Acad. Sci. U.S.A. 112, 11229–11234 10.1073/pnas.1508187112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78. Li X., and Coffino P. (1994) Distinct domains of antizyme required for binding and proteolysis of ornithine decarboxylase. Mol. Cell. Biol. 14, 87–92 10.1128/MCB.14.1.87 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79. Auvinen M., Paasinen A., Andersson L. C., and Hölttä E. (1992) Ornithine decarboxylase activity is critical for cell transformation. Nature 360, 355–358 10.1038/360355a0 [DOI] [PubMed] [Google Scholar]
  • 80. Olsen R. R., and Zetter B. R. (2011) Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer. Mol. Cancer Res. 9, 1285–1293 10.1158/1541-7786.MCR-11-0178 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Gruendler C., Lin Y., Farley J., and Wang T. (2001) Proteasomal degradation of Smad1 induced by bone morphogenetic proteins. J. Biol. Chem. 276, 46533–46543 10.1074/jbc.M105500200 [DOI] [PubMed] [Google Scholar]
  • 82. Lim S. K., and Gopalan G. (2007) Antizyme1 mediates AURKAIP1-dependent degradation of Aurora-A. Oncogene 26, 6593–6603 10.1038/sj.onc.1210482 [DOI] [PubMed] [Google Scholar]
  • 83. Newman R. M., Mobascher A., Mangold U., Koike C., Diah S., Schmidt M., Finley D., and Zetter B. R. (2004) Antizyme targets cyclin D1 for degradation: a novel mechanism for cell growth repression. J. Biol. Chem. 279, 41504–41511 10.1074/jbc.M407349200 [DOI] [PubMed] [Google Scholar]
  • 84. Dulloo I., Gopalan G., Melino G., and Sabapathy K. (2010) The antiapoptotic ΔNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway. Proc. Natl. Acad. Sci. U.S.A. 107, 4902–4907 10.1073/pnas.0906782107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85. Bercovich Z., Snapir Z., Keren-Paz A., and Kahana C. (2011) Antizyme affects cell proliferation and viability solely through regulating cellular polyamines. J. Biol. Chem. 286, 33778–33783 10.1074/jbc.M111.270637 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86. Murai N., Murakami Y., Tajima A., and Matsufuji S. (2018) Novel ubiquitin-independent nucleolar c-Myc degradation pathway mediated by antizyme 2. Sci. Rep. 8, 3005 10.1038/s41598-018-21189-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Chin S. F., Teschendorff A. E., Marioni J. C., Wang Y., Barbosa-Morais N. L., Thorne N. P., Costa J. L., Pinder S. E., van de Wiel M. A., Green A. R., Ellis I. O., Porter P. L., Tavaré S., Brenton J. D., Ylstra B., and Caldas C. (2007) High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. 8, R215 10.1186/gb-2007-8-10-r215 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. Jung M. H., Kim S. C., Jeon G. A., Kim S. H., Kim Y., Choi K. S., Park S. I., Joe M. K., and Kimm K. (2000) Identification of differentially expressed genes in normal and tumor human gastric tissue. Genomics 69, 281–286 10.1006/geno.2000.6338 [DOI] [PubMed] [Google Scholar]
  • 89. Schaner M. E., Ross D. T., Ciaravino G., Sorlie T., Troyanskaya O., Diehn M., Wang Y. C., Duran G. E., Sikic T. L., Caldeira S., Skomedal H., Tu I.-P., Hernandez-Boussard T., Johnson S. W., O'Dwyer P. J., et al. (2003) Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell. 14, 4376–4386 10.1091/mbc.e03-05-0279 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90. van Duin M., van Marion R., Vissers K., Watson J. E., van Weerden W. M., Schröder F. H., Hop W. C., van der Kwast T. H., Collins C., and van Dekken H. (2005) High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 44, 438–449 10.1002/gcc.20259 [DOI] [PubMed] [Google Scholar]
  • 91. Choi K. S., Suh Y. H., Kim W.-H., Lee T. H., and Jung M. H. (2005) Stable siRNA-mediated silencing of antizyme inhibitor: regulation of ornithine decarboxylase activity. Biochem. Biophys. Res. Commun. 328, 206–212 10.1016/j.bbrc.2004.11.172 [DOI] [PubMed] [Google Scholar]
  • 92. Olsen R. R., Chung I., and Zetter B. R. (2012) Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo. Amino Acids 42, 549–558 10.1007/s00726-011-1032-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93. Chen L., Li Y., Lin C. H., Chan T. H., Chow R. K., Song Y., Liu M., Yuan Y.-F., Fu L., Kong K. L., Qi L., Li Y., Zhang N., Tong A. H., Kwong D. L., et al. (2013) Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat. Med. 19, 209–216 10.1038/nm.3043 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94. Qin Y.-R., Qiao J.-J., Chan T. H., Zhu Y.-H., Li F.-F., Liu H., Fei J., Li Y., Guan X.-Y., and Chen L. (2014) Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res. 74, 840–851 10.1158/0008-5472.CAN-13-2545 [DOI] [PubMed] [Google Scholar]
  • 95. Shigeyasu K., Okugawa Y., Toden S., Miyoshi J., Toiyama Y., Nagasaka T., Takahashi N., Kusunoki M., Takayama T., Yamada Y., Fujiwara T., Chen L., and Goel A. (2018) AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. JCI Insight 3, 99976 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96. Hu X., Chen J., Shi X., Feng F., Lau K. W., Chen Y., Chen Y., Jiang L., Cui F., Zhang Y., Xu X., and Li J. (2017) RNA editing of AZIN1 induces the malignant progression of non-small-cell lung cancers. Tumor Biol. 39, 10.1177/1010428317700001 [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES